Heterocyclic compounds as inhibitors of factor VIIa

Details Heterocyclic compounds as inhibitors of factor VIIa Heterocyclic compounds as inhibitors of factor VIIa

2005-12-07

2009-08-18

Davis, Zinna N (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S311000, C514S314000, C514S352000, C514S381000, C514S383000, C514S394000, C514S397000, C514S406000, C546S139000, C546S148000, C546S152000, C546S268100, C546S304000, C548S254000, C548S262200, C548S302700, C548S335100

Reexamination Certificate

active

07576098

ABSTRACT:
The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

REFERENCES:
patent: 5023236 (1991-06-01), Edgington et al.
patent: 5843442 (1998-12-01), Soule et al.
patent: 5866542 (1999-02-01), Vlasuk et al.
patent: 6140353 (2000-10-01), Ackermann et al.
patent: 6242644 (2001-06-01), Ackermann et al.
patent: 6271237 (2001-08-01), Galemmo, Jr. et al.
patent: 6632815 (2003-10-01), Zhu et al.
patent: 6642252 (2003-11-01), Bisacchi et al.
patent: 6713467 (2004-03-01), Bisacchi et al.
patent: 6906084 (2005-06-01), Nazaré et al.
patent: 6953802 (2005-10-01), Konradi et al.
patent: 2002/0151534 (2002-10-01), Ries et al.
patent: 2004/0006065 (2004-01-01), Glunz
patent: 2004/0176375 (2004-09-01), Bisacchi et al.
patent: 2004/0204412 (2004-10-01), Glunz et al.
patent: 2005/0009895 (2005-01-01), Priestley et al.
patent: 2005/0038030 (2005-02-01), Zhang
patent: 2005/0043336 (2005-02-01), Hennequin et al.
patent: 2005/0054662 (2005-03-01), Hennequin et al.
patent: 2006/0166997 (2006-07-01), Zhang et al.
patent: 2007/0003539 (2007-01-01), Zhang et al.
patent: WO 02/00651 (2002-01-01), None
patent: WO 02/062778 (2002-08-01), None
patent: WO 02/064578 (2002-08-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 02/064599 (2002-08-01), None
patent: WO2003/047512 (2003-06-01), None
patent: WO2004/000214 (2003-12-01), None
patent: WO2004/002406 (2004-01-01), None
patent: WO2004/072101 (2004-08-01), None
patent: WO2004/110374 (2004-12-01), None
West, Anthony R., Solid State Chemistry and Its Applications, Wiley, New York, 1988, pp. 358 & 365.
U.S. Appl. No. 11/328,479, filed Jan. 9, 2006, Zhang et al.
Carson, S.D. et al., “The role of tissue factor in the production of thrombin”, Blood Coagulation and Fibrinolysis, vol. 4, pp. 281-292 (1993).
Colman, R. W., Chapter 6: “Contact Activation Pathway: Inflammatory, Fibrinolytic, Anticoagulant, Antiadhesive, and Antiangiogenic Activities”, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4thEd., Lippincott Williams & Wilkins, publ., Colman, R.W. et al., eds., pp. 103-121 (2001).
Girard, T.J. et al., “The role of tissue factor/factor VIIa in the pathophysiology of acute thrombotic formation”, Current Opinion in Pharmacology, vol. 1, pp. 159-163 (2001).
Goodnight, S.H. et al., Chapter 4: “Screening Tests of Hemostasis”, Disorders of Hemostasis and Thrombosis: A Clinical Guide, The McGraw-Hill Companies, publ., pp. 41-51 (2001).
Schmaier, A.H., Chapter 5: “Contact Activation”, Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 4thEd., Lippincott Williams & Wilkins, publ., Colman, R.W. et al., eds., pp. 105-127 (2001).

Affiliated with

Also associated with

Rating

Heterocyclic compounds as inhibitors of factor VIIa does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Heterocyclic compounds as inhibitors of factor VIIa, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Heterocyclic compounds as inhibitors of factor VIIa will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4134383